Abstract
Systematic review and meta-analysis of accuracy of tumor origin detection in blood cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) assays in the general population.
Author
person
Joo Hee Park
Northwestern University, Chicago, IL
info_outline
Joo Hee Park, Youjin Oh, Liam Il-Young Chung, Richard Duan, Trie Arni Djunadi, Sung Mi Yoon, Zunairah Shah, Chan Mi Jung, Ilene Hong, Leeseul Kim, Horyun Choi, Young Kwang Chae
Full text
Authors
person
Joo Hee Park
Northwestern University, Chicago, IL
info_outline
Joo Hee Park, Youjin Oh, Liam Il-Young Chung, Richard Duan, Trie Arni Djunadi, Sung Mi Yoon, Zunairah Shah, Chan Mi Jung, Ilene Hong, Leeseul Kim, Horyun Choi, Young Kwang Chae
Organizations
Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern Memorial Hospital, Chicago, IL, Louis A Weiss Memorial Hospital, Chicago, IL, Northwestern University, Evanston, IL, Ascension Saint Francis Hospital, Evanston, IL, University of Hawaii Internal Medicine Residency Program, Honolulu, HI
Abstract Disclosures
Research Funding
No funding received
None.
Background:
Among recently developed blood-based MCED tests, the ability to determine the location of tumors is pivotal to guiding appropriate treatment. We systematically reviewed and statistically examined the accuracy of tumor of origin predictions among blood-based MCED tests.
Methods:
Original articles were searched from Pubmed, Cochrane, and Embase for blood-based screening tests, multiple cancer types, and asymptomatic human subjects. We excluded studies with small samples (n < 30), non-screening, and non-blood-based tests. For cfDNA-based assays, measurements of diagnostic accuracy were pooled for meta-analysis.
Results:
Of 1,074 records identified and screened, five case-control studies and one cohort study that used cfDNA-based diagnostic tests were analyzed. Accuracy of tissue-of-origin (TOO) prediction for 3,895 cancer samples across cancer types was 0.79 (95% CI 0.66 - 0.90). Among six cancer types, colorectal cancers had the highest accuracy and liver & bile duct cancers had the lowest, although the difference was statistically insignificant (0.89 (95% CI 0.79-0.97) vs. 0.68 (95% CI 0.40-0.90)). Additionally, cases were most frequently misclassified as colorectal cancer (Table 1). The information for localizing TOO was derived from methylation patterns of cfDNA in four studies, fragmentation profiles of cfDNA in another study, and combination of mutations in cfDNA and protein markers in the last study.
Conclusions:
Our results demonstrate that the primary site of cancers was accurately discerned in 79% of cases by MCED tests. However, performance varies across cancer types. Further research on performance based on cancer stages and in combination with other molecular profiling is warranted.
Pooled accuracy of prediction of tissue-of-origin (TOO) and frequently ‘misclassified as’ cancer types.
Events/Total
Accuracy of prediction
Misclassification
Type
Frequency
Total
3,229/3,895
0.79
Colorectal
656/743
0.90
Upper GI
26/573
Breast
9/573
Breast
461/557
0.88
Colorectal
20/349
Pancreas & GB
4/349
Lung
4/349
Ovarian
136/164
0.85
Colorectal
16/147
Uterus
13/147
Pancreatic & GB
289/338
0.82
Colorectal
12/317
Upper GI
10/317
Upper GI
226/313
0.75
Colorectal
39/261
Lung
10/261
Lung
553/681
0.76
Colorectal
29/585
Head and neck
8/585
Liver & Bile duct
95/144
0.68
Colorectal
13/220
Pancreas & GB
8/220
Abbreviations: CI = confidence interval; GB = gallbladder, Upper GI = stomach and esophagus.
6 organizations
Organization
Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer CenterOrganization
Northwestern Memorial Hospital, Chicago, ILOrganization
Louis A Weiss Memorial HospitalOrganization
Ascension Saint Francis Hospital